Navigation Links
James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
Date:8/6/2013

CUMBERLAND, R.I., Aug. 6, 2013 /PRNewswire/ -- Neurotech Pharmaceuticals, a biotechnology company developing sight-saving therapies for chronic retinal disease, announced today that James Mazzo was appointed the company's Executive Chairman.  Mazzo, a long time leader in the ophthalmic industry, is the former CEO of Abbott Medical Optics (AMO), is an Operating Partner at Versant Ventures and was recently named Chairman and CEO of AcuFocus, a Versant portfolio company.

(Logo: http://photos.prnewswire.com/prnh/20130806/NE59269LOGO)

As Executive Chairman, Mazzo will engage with the Neurotech team to advance the Company's novel technology platform through the clinical development stage toward market availability.

"Neurotech's technology is truly groundbreaking and I am confident it will bring improved therapy to serious retinal diseases such as wet and dry age-related macular degeneration, and macular telangiectasia – diseases that ultimately cause blindness," said James Mazzo.

Neurotech's patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that enables the continuous delivery of protein drugs directly into the vitreous of the eye.  The Company has demonstrated that a single living ECT implant can treat a diseased retina for two years or more, thereby eliminating the need for monthly injections, the conventional approach to treating retinal disease.  ECT systems can produce all classes of modern biotherapeutic drugs, including peptides, hormones, monoclonal antibodies, antibody fragments and next generation alternative scaffolds.  As a robust technology platform, ECT can be adapted to also generate protein drugs targeting uveitis, glaucoma and other ophthalmic indications.

"I admire Jim's commitment to and extensive accomplishments in the ophthalmic world.  We are honored to have him help lead our company as we advance Neurotech into the next phase of growth," said Ted Danse, President and CEO of Neurotech.

Jim Mazzo's 35-year career in the healthcare industry includes seven years as Chairman, President and CEO of Advanced Medical Optics (AMO), which was sold to Abbott Labs in 2009 for $2.8 billion. He was previously with Allergan for over 20 years in a variety of expanding roles, working and living in the U.S., England, Italy and Canada. He led the spinoff of AMO from Allergan in 2002, expanding the business into a $1 billion industry-leading, publicly-traded corporation. Most recently, he has served as Senior Vice President, Abbott Laboratories and President, Abbott Medical Products.

William J. Link, PhD, Managing Director at Versant Ventures and a Neurotech board member, said, "Jim's talents are tremendously applicable to Neurotech.  We look forward to working together to further Neurotech's promising technology in the treatment of retinal diseases and help people retain their sight."

About Neurotech Pharmaceuticals, Inc.

Neurotech is developing sight-saving therapeutics for the treatment of chronic retinal diseases.  Utilizing its transformational technology, Encapsulated Cell Technology (ECT), Neurotech is developing intraocular implants that provide controlled, sustained and long-term delivery of therapeutic proteins to the back of the eye, thereby overcoming a major obstacle in the treatment of retinal disease. The Company's lead ECT-based product candidates include NT-503 for the treatment of wet AMD (Phase 2), and Renexus® (NT-501) for the treatment of Macular Telangiectasia (pre-Phase 2).  To learn more, please visit www.neurotechusa.com.


'/>"/>
SOURCE Neurotech USA
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Eurofins MWG Operon, Inc. Names James Corne as Director of Marketing
2. StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500
3. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
4. Tissue Culture Biologicals, Inc. Hires James D. Titus to Lead New Expansion and Branding Development Effort
5. ABC Announces Recipients of James A. Duke Excellence in Botanical Literature Award
6. Dr. James Douglas Adds Human Growth Hormone (HGH) Therapy to IVF Protocols for Poor Responding Patients
7. James bond: A graphene/nanotube hybrid
8. Laureate Biopharma Names James D. Utterback to Board of Directors
9. Herbal Microscopy Book Receives American Botanical Councils James A. Duke Book Award
10. InspireMD Appoints Dr. James Barry to Its Board of Directors
11. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
(Date:10/9/2017)... FL (PRWEB) , ... October 09, 2017 , ... The ... scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... industry is faced with the challenge of how to continue to feed a growing ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... line of medical marijuana products targeting the needs of consumers who are incorporating ... Kindred takes place in Phoenix, Arizona. , As operators of two successful Valley ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):